Abstract
Background: The receptor for advanced glycation end-products (RAGE) is implicated in pancreatic tumorigenesis. Activating Kras mutations and p16 inactivation are genetic abnormalities most commonly detected as pancreatic ductal epithelium progresses from intraepithelial neoplasia (PanIN) to adenocarcinoma (PDAC). Objective: The aim of this study was to evaluate the effect of RAGE (or AGER) deletion on the development of PanIN and PDAC in conditional Kras G12D mice. Materials and Methods: Pdx1-Cre; LSL-Kras G12D/+ mice were crossed with RAGE -/- mice to generate Pdx1-Cre; LSL-Kras G12D/+; RAGE -/- mice. Pdx1-Cre; LSL-Kras G12D/+; p16 Ink4a-/- mice were crossed with RAGE -/- mice to generate Pdx1-Cre; LSL-Kras G12D/+; p16 Ink4a-/-; RAGE -/- mice. Pancreatic ducts were scored and compared to the relevant RAGE +/+ controls. Results: At 16 weeks of age, Pdx1-Cre; LSL-Kras G12D/+; RAGE -/- mice had significantly fewer high-grade PanIN lesions than Pdx1-Cre; LSL-Kras G12D/+; RAGE +/+ controls. At 12 weeks of age, none of the Pdx1-Cre; LSL-Kras G12D/+; p16 Ink4a-/-; RAGE -/- mice had PDAC compared to a 45. 5% incidence of PDAC in Pdx1-Cre; LSL-Kras G12D/+; p16 Ink4a-/-; RAGE +/+ controls. Finally, Pdx1-Cre; LSL-Kras G12D/+; p16 Ink4a-/-; RAGE -/- mice also displayed markedly longer median survival. Conclusion: Loss of RAGE function inhibited the development of PanIN and progression to PDAC and significantly prolonged survival in these mouse models. Further work is needed to target the ligand-RAGE axis for possible early intervention and prophylaxis in patients at risk for developing pancreatic cancer.
Original language | English |
---|---|
Pages (from-to) | 104-112 |
Number of pages | 9 |
Journal | Journal of Gastrointestinal Surgery |
Volume | 16 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2012 |
Externally published | Yes |
Keywords
- AGER
- Kras
- PanIN
- Pancreatic adenocarcinoma
- Pancreatic cancer
- Pdx1-Cre
- RAGE
- RAGE mice
- p16